Abstract
SummaryA unique live attenuated respiratory syncytial virus vaccine that is administered parenterally is described. Nineteen of 22 initially seronegative children, 7-32 months of age, developed homologous circulating neutralizing antibody against the virus and a portion were shown to have present demonstrable antibody in their nasal secretions. None of the children developed illness that could be ascribed to the vaccine, and there was no evident contagious spread of the vaccine virus to susceptible contacts. The vaccine is of considerable promise and trials to determine protective efficacy are being pursued. Seroepidemiologic investigations revealed that only 33 of 66 children 6-48 months of age and residing in an open population had detectable circulating neutralizing antibody against the virus.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
